ClinicalTrials.Veeva

Menu

Vivaer® Procedure for Treatment of Nasal Airway Obstruction Study (VATRAC)

A

Aerin Medical

Status

Active, not recruiting

Conditions

Nasal Airway Obstruction

Treatments

Device: Sham
Device: Vivaer ARC Stylus

Study type

Interventional

Funder types

Industry

Identifiers

NCT04549545
CTP1006

Details and patient eligibility

About

The purpose of this study is to compare the Vivaer procedure with radiofrequency (RF) energy to sham procedure for treatment of nasal airway obstruction (NAO).

Full description

The purpose of this study is to compare the Vivaer procedure for treatment of nasal airway obstruction (NAO) with a sham procedure that simulates the actual procedure as closely as possible absent the delivery of radiofrequency (RF) energy to the nasal tissue.

Enrollment

119 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 18 to 85 years (inclusively).

  2. Willing and able to provide informed consent.

  3. Willing and able to comply with the subject-specific requirements outlined in the Study Protocol.

  4. Seeking treatment for nasal obstruction and willing to undergo an office-based procedure.

  5. Baseline Nasal Obstruction Symptom Evaluation (NOSE) Scale score ≥ 55.

  6. Nasal valve is a primary or significant contributor to the patient's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the patient has a positive response to any of the following temporary measures (based on patient history or office exam):

    • Use of external nasal dilator strips (eg, Breathe Right Strips)
    • Use of internal nasal dilator cones
    • Modified Cottle Maneuver (manual elevation of the lateral nasal wall using a small instrument or cotton-tipped applicator to open the nasal valve)
    • Cottle Maneuver (manual lateral retraction of the cheek to open the nasal valve)
  7. Dissatisfaction with medical management as judged by the patient. Defined as failed medical therapy (eg, decongestants, antihistamines, and/or nasal sprays for an appropriate period of time), but a positive response to internal or external nasal dilators.

Exclusion criteria

  1. Prior surgery of the lateral nasal wall, including cephalic resection of the lower lateral cartilage, dome division or suture plication, alar graft or spreader graft placement.
  2. Rhinoplasty, septoplasty, inferior turbinate reduction or functional endoscopic sinus surgery (FESS) within the preceding 3 months.
  3. Severe case of any of the following: septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be the primary contributor to the patient's nasal obstruction symptoms and warranting surgical intervention.
  4. Any adjunctive surgical nasal procedure planned on the same day or within 6 months after the Vivaer procedure.
  5. Known or suspected to be pregnant or is lactating.
  6. Participating in another clinical research study.
  7. Other medical conditions which in the opinion of the investigator would predispose the patient to poor wound healing or increased surgical risk, or poor compliance with the requirements of the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Single Blind

119 participants in 2 patient groups

Vivaer Procedure
Active Comparator group
Description:
The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session. Each side of the nose will be treated with up to four (4) non-overlapping applications of RF energy at the junction of the upper and lower lateral cartilage on the lateral nasal wall. Treatment settings to be used are: temperature 60° C, power 4 watts, treatment time 18 seconds, and cooling time 12 seconds. No repeat ("touch up") procedures will be permitted after the initial procedure through the end of the study (24 months).
Treatment:
Device: Vivaer ARC Stylus
Sham Control Procedure
Sham Comparator group
Description:
The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
Treatment:
Device: Sham

Trial documents
2

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems